ArticleCancer medicine2016
Racial disparities in renal cell carcinoma: a single-payer healthcare experience.
Article in Cancer medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Medicaid Expansion and Overall Mortality Among Individuals With Renal Cell Carcinoma.The Journal of surgical research · 2026Article
- Temporal trends and demographic-geographic disparities in kidney Cancer mortality in the United States, 1999-2023.Preventive medicine reports · 2025Article
- Racial differences in kidney cancer histology and outcome: A nationwide study from the UroCCR Cohort.Cancer · 2025Article
- Evaluating Patient Adherence and Persistence to Tyrosine-Kinase Inhibitors for Metastatic Renal Cell Carcinoma: A Retrospective Analysis of Real-World Data.Clinical Medicine Insights. Oncology · 2025Article
- Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma.JNCI cancer spectrum · 2023Article
- Renal Cell Carcinoma in End-Stage Renal Disease: A Retrospective Study in Patients from Hungary.Pathobiology : journal of immunopathology, molecular and cellular biology · 2023Article
- Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents.Clinical genitourinary cancer · 2022Article
- Impacts of Neighborhood Characteristics and Surgical Treatment Disparities on Overall Mortality in Stage I Renal Cell Carcinoma Patients.International journal of environmental research and public health · 2022Article
- Kidney cancer mortality disparities among Hispanics in the US.Cancer epidemiology · 2021Article
- Article
- Epidemiology of Renal Cell Carcinoma.World journal of oncology · 2020Review
- Racial/ethnic disparities in renal cell carcinoma: Increased risk of early-onset and variation in histologic subtypes.Cancer medicine · 2019Article
- Systemic therapy for metastatic renal cell carcinoma-is timing everything?Annals of translational medicine · 2019Article
- A real-world 1:1 propensity-matched study revealed unmarried status was independently associated with worse survival for patients with renal clear cell carcinoma.Journal of Cancer · 2019Article
- Ethnic disparities in renal cell carcinoma: An analysis of Hispanic patients in a single-payer healthcare system.International journal of urology : official journal of the Japanese Urological Association · 2017Article
- Racial disparities in renal cell carcinoma: a single-payer healthcare experience.Cancer medicine · 2016Article
- Analysis and Prediction of the Survival Trends of Patients with Clear-Cell Renal Cell Carcinoma: A Model-Based Period Analysis, 2001-2015.Cancer control : journal of the Moffitt Cancer CenterArticle
- Racial-Ethnic Comparisons in Surgical Treatment and Outcomes of Non-Metastatic Renal Cell Cancer in an Equal Access Health System.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Significant racial disparities in survival for renal cell carcinoma (RCC) exist between white and black patients. Differences in access to care and comorbidities are possible contributors. To investigate if racial disparities persist when controlling for access to care, we analyzed data from a single-payer healthcare system. As part of a case-control study within the Kaiser Permanente Northern California system, pathologic and clinical records were obtained for RCC cases (2152 white, 293 black) diagnosed from 1998 to 2008. Patient demographics, comorbidities, tumor characteristics, and treatment status were compared. Overall survival and disease-specific survival (DSS) were calculated by the Kaplan-Meier method. A Cox proportion hazards model estimated the independent associations of race, comorbidity, and clinicopathologic variables with DSS. We found that compared to white patients, black patients were diagnosed at a younger age (median 62 vs. 66 years, P < 0.001), were more likely to have papillary RCC (15% vs. 5.2%, P < 0.001), and had similar rates of surgical treatment (78.8% vs. 77.9%, P = 0.764). On multivariate analysis, advanced American Joint Committee on Cancer (AJCC) stage, lack of surgical treatment, larger tumor size, and higher grade were predictors of worse DSS. Race was not an independent predictor of survival. Therefore, we conclude that within a single healthcare system, differences in characteristics of black and white patients with RCC persist; black patients had different comorbidities, were younger, and had decreased tumor stage. However, unlike other series, race was not an independent predictor of DSS, suggesting that survival differences in large registries may result from barriers to healthcare access and/or comorbidity rather than disease biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.